DGAP-News: Raptor Pharmaceutical Corp. Signs Collaborative Research and Development Agreement With NIDDK on Phase 2b Clinical Trial of RP104 (DR Cysteamine Tablets) in Non-Alcoholic Steatohepatitis (–NASH–)
Raptor Pharmaceutical Corp.
19.12.2011 12:30
—————————————————————————
Phase 2b Trial Anticipated to Start in Q1 2012
Company to Host NASH Event at JP Morgan Healthcare Conference
NOVATO, Calif., Dec. 19, 2011 (GLOBE NEWSWIRE) — Raptor Pharmaceutical Corp.
(–Raptor– or the –Company–) (Nasdaq:RPTP), today announced the signing of a
cooperative research and development agreement (–CRADA–) with the National
Ins
